vTv Therapeutics to join Morgan Stanley fireside chat

vTv Therapeutics Inc. filed a current report describing its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference.

Rhea-AI Filing Summary

vTv Therapeutics Inc. filed a current report describing its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. On September 10, 2025, the company will join a fireside chat scheduled from 2:35 to 3:10 p.m. EST, available as a live audio webcast and on demand.

The company notes that a link to the webcast will be posted on its website. This communication is furnished under Regulation FD and is expressly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did vTv Therapeutics Inc. (VTVT) disclose in this 8-K?

vTv Therapeutics Inc. disclosed that it will participate in a fireside chat during the Morgan Stanley 23rd Annual Global Healthcare Conference. The company emphasized that this information is furnished under Regulation FD and is not deemed filed or incorporated by reference into other securities law filings.

When will vTv Therapeutics (VTVT) appear at the Morgan Stanley healthcare conference?

vTv Therapeutics will appear at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. The company is scheduled for a fireside chat from 2:35 to 3:10 p.m. Eastern Time, according to the details provided in the current report disclosure.

How can listeners access vTv Therapeutics’ Morgan Stanley fireside chat webcast?

The fireside chat will be hosted as a live audio webcast and also available on demand. vTv Therapeutics states that a link to the webcast will be posted on the company’s website, allowing interested parties to access the session both live and later.

Is the vTv Therapeutics conference webcast information considered filed under the Exchange Act?

The company specifies that the information in this Regulation FD disclosure is furnished, not filed, for purposes of Section 18 of the Exchange Act. It further notes it will not be incorporated by reference into any Securities Act or Exchange Act filing unless expressly stated.

What is the subject of vTv Therapeutics’ Item 7.01 Regulation FD disclosure?

Item 7.01 covers vTv Therapeutics’ participation in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The disclosure focuses on the timing of the session, its webcast format, and clarifies the legal treatment of this information under securities law provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 01:03 PM Learn about SEC filing dates

FALSE0001641489Nasdaq00016414892025-09-102025-09-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported):  September 10, 2025

vTv Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-37524			47-3916571
(State or other jurisdiction of incorporation)			(Commission File No.)			(IRS Employer Identification No.)

3980 Premier Drive, Suite 310

High Point, NC 27265

(Address of principal executive offices)

(336) 841-0300

(Registrant’s telephone number, including area code)

NOT APPLICABLE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Class A common stock, par value $0.01 per share			VTVT			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure

On September 10, 2025, vTv Therapeutics, Inc., (the "Company") will participate in a fireside chat from 2:35 PM - 3:10 PM EST during the Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will be hosted live via audio webcast and will also be available on demand. A link to the live web hosted fireside chat will posted on the Company's web site.

The information in this Item 7.01 shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act, nor shall it be deemed to be incorporated by reference in any filing under the 33 Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

			VTV THERAPEUTICS INC.
			By:			/s/ Paul J. Sekhri
			Name:			Paul J. Sekhri
			Title:			President, Chief Executive Officer and Executive Chairperson

Dated: September 10, 2025